185 related articles for article (PubMed ID: 36946611)
21. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
22. Association of CD2AP neuronal deposits with Braak neurofibrillary stage in Alzheimer's disease.
Camacho J; Rábano A; Marazuela P; Bonaterra-Pastra A; Serna G; Moliné T; Ramón Y Cajal S; Martínez-Sáez E; Hernández-Guillamon M
Brain Pathol; 2022 Jan; 32(1):e13016. PubMed ID: 34514662
[TBL] [Abstract][Full Text] [Related]
23. 18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases.
Soleimani-Meigooni DN; Iaccarino L; La Joie R; Baker S; Bourakova V; Boxer AL; Edwards L; Eser R; Gorno-Tempini ML; Jagust WJ; Janabi M; Kramer JH; Lesman-Segev OH; Mellinger T; Miller BL; Pham J; Rosen HJ; Spina S; Seeley WW; Strom A; Grinberg LT; Rabinovici GD
Brain; 2020 Dec; 143(11):3477-3494. PubMed ID: 33141172
[TBL] [Abstract][Full Text] [Related]
24. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology.
Arai H; Morikawa Y; Higuchi M; Matsui T; Clark CM; Miura M; Machida N; Lee VM; Trojanowski JQ; Sasaki H
Biochem Biophys Res Commun; 1997 Jul; 236(2):262-4. PubMed ID: 9240421
[TBL] [Abstract][Full Text] [Related]
25. Phosphorylated α-synuclein and phosphorylated tau-protein in sural nerves may contribute to differentiate Parkinson's disease from multiple system atrophy and progressive supranuclear paralysis.
Rong Z; Shen F; Wang Y; Sun L; Wu J; Zhang H; Yuan Y; Jiang W; Li X; Ji P; Zhang K
Neurosci Lett; 2021 Jun; 756():135964. PubMed ID: 34022266
[TBL] [Abstract][Full Text] [Related]
26. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy.
Borroni B; Malinverno M; Gardoni F; Alberici A; Parnetti L; Premi E; Bonuccelli U; Grassi M; Perani D; Calabresi P; Di Luca M; Padovani A
Neurology; 2008 Nov; 71(22):1796-803. PubMed ID: 18971445
[TBL] [Abstract][Full Text] [Related]
27. Cerebrospinal fluid neurofilament light and tau protein as mortality biomarkers in parkinsonism.
Constantinescu R; Rosengren L; Eriksson B; Blennow K; Axelsson M
Acta Neurol Scand; 2019 Aug; 140(2):147-156. PubMed ID: 31070772
[TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy.
Holmberg B; Johnels B; Blennow K; Rosengren L
Mov Disord; 2003 Feb; 18(2):186-90. PubMed ID: 12539213
[TBL] [Abstract][Full Text] [Related]
29. Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease.
von Euler Chelpin M; Söderberg L; Fälting J; Möller C; Giorgetti M; Constantinescu R; Blennow K; Zetterberg H; Höglund K
J Parkinsons Dis; 2020; 10(4):1429-1442. PubMed ID: 33016895
[TBL] [Abstract][Full Text] [Related]
30. Differential vulnerability of the dentate gyrus to tauopathies in dementias.
Kawles A; Minogue G; Zouridakis A; Keszycki R; Gill N; Nassif C; Coventry C; Zhang H; Rogalski E; Flanagan ME; Castellani R; Bigio EH; Mesulam MM; Geula C; Gefen T
Acta Neuropathol Commun; 2023 Jan; 11(1):1. PubMed ID: 36597124
[TBL] [Abstract][Full Text] [Related]
31. CSF tau microtubule-binding region identifies pathological changes in primary tauopathies.
Horie K; Barthélemy NR; Spina S; VandeVrede L; He Y; Paterson RW; Wright BA; Day GS; Davis AA; Karch CM; Seeley WW; Perrin RJ; Koppisetti RK; Shaikh F; Lago AL; Heuer HW; Ghoshal N; Gabelle A; Miller BL; Boxer AL; Bateman RJ; Sato C
Nat Med; 2022 Dec; 28(12):2547-2554. PubMed ID: 36424467
[TBL] [Abstract][Full Text] [Related]
32. Evaluating the Effect of Alzheimer's Disease-Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy.
Garcia-Cordero I; Anastassiadis C; Khoja A; Morales-Rivero A; Thapa S; Vasilevskaya A; Davenport C; Sumra V; Couto B; Multani N; Taghdiri F; Anor C; Misquitta K; Vandevrede L; Heuer H; Tang-Wai D; Dickerson B; Pantelyat A; Litvan I; Boeve B; Rojas JC; Ljubenkov P; Huey E; Fox S; Kovacs GG; Boxer A; Lang A; Tartaglia MC;
Ann Neurol; 2024 Jul; 96(1):99-109. PubMed ID: 38578117
[TBL] [Abstract][Full Text] [Related]
33. Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders.
Schulz I; Kruse N; Gera RG; Kremer T; Cedarbaum J; Barbour R; Zago W; Schade S; Otte B; Bartl M; Hutten SJ; Trenkwalder C; Mollenhauer B
Mov Disord; 2021 Dec; 36(12):2874-2887. PubMed ID: 34363416
[TBL] [Abstract][Full Text] [Related]
34. Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy brains.
Malarte ML; Gillberg PG; Kumar A; Bogdanovic N; Lemoine L; Nordberg A
Mol Psychiatry; 2023 Mar; 28(3):1272-1283. PubMed ID: 36447011
[TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy.
Compta Y; Giraldo DM; Muñoz E; Antonelli F; Fernández M; Bravo P; Soto M; Cámara A; Torres F; Martí MJ;
Parkinsonism Relat Disord; 2018 Jan; 46():16-23. PubMed ID: 29107645
[TBL] [Abstract][Full Text] [Related]
36. Molecular Processing of Tau Protein in Progressive Supranuclear Palsy: Neuronal and Glial Degeneration.
Martínez-Maldonado A; Ontiveros-Torres MÁ; Harrington CR; Montiel-Sosa JF; Prandiz RG; Bocanegra-López P; Sorsby-Vargas AM; Bravo-Muñoz M; Florán-Garduño B; Villanueva-Fierro I; Perry G; Garcés-Ramírez L; de la Cruz F; Martínez-Robles S; Pacheco-Herrero M; Luna-Muñoz J
J Alzheimers Dis; 2021; 79(4):1517-1531. PubMed ID: 33459640
[TBL] [Abstract][Full Text] [Related]
37. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF.
Kahle PJ; Jakowec M; Teipel SJ; Hampel H; Petzinger GM; Di Monte DA; Silverberg GD; Möller HJ; Yesavage JA; Tinklenberg JR; Shooter EM; Murphy GM
Neurology; 2000 Apr; 54(7):1498-504. PubMed ID: 10751266
[TBL] [Abstract][Full Text] [Related]
38. Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration.
Riku Y; Iwasaki Y; Ishigaki S; Akagi A; Hasegawa M; Nishioka K; Li Y; Riku M; Ikeuchi T; Fujioka Y; Miyahara H; Sone J; Hattori N; Yoshida M; Katsuno M; Sobue G
Brain; 2022 Aug; 145(8):2769-2784. PubMed ID: 35274674
[TBL] [Abstract][Full Text] [Related]
39. Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid.
Boman A; Svensson S; Boxer A; Rojas JC; Seeley WW; Karydas A; Miller B; Kågedal K; Svenningsson P
J Parkinsons Dis; 2016 Apr; 6(2):307-15. PubMed ID: 27061067
[TBL] [Abstract][Full Text] [Related]
40. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
